SLC5A2 and cardiovascular disorder: SGLT2i: sodium-glucose cotransporter-2 inhibitor; GLP-1 RA: glucagon-like peptide-1 receptor agonist; T2D: type 2 diabetes; CV: cardiovascular; MACE: major adverse cardiovascular events; HF: heart failure; hosp: hospitalization; MI: myocardial infarction; HR: hazard ratio; CI: confidence interval; FU: follow-up; DKA: diabetic ketoacidosis; PS: propensity score; CVD: cardiovascular disease